|
AFF4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69090999999622E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.68320000000822E-05 |
| Normal-vs-Stage2 |
1.069780E-02 |
| Normal-vs-Stage3 |
2.00399999999989E-05 |
| Normal-vs-Stage4 |
5.97169999999592E-05 |
| Stage1-vs-Stage2 |
6.785800E-01 |
| Stage1-vs-Stage3 |
3.857800E-01 |
| Stage1-vs-Stage4 |
3.361800E-01 |
| Stage2-vs-Stage3 |
3.399600E-01 |
| Stage2-vs-Stage4 |
2.865000E-01 |
| Stage3-vs-Stage4 |
7.705200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.9260599999904E-05 |
| Normal-vs-AfricanAmerican |
2.579800E-01 |
| Normal-vs-Asian |
4.47759999999686E-05 |
| Caucasian-vs-AfricanAmerican |
8.792000E-02 |
| Caucasian-vs-Asian |
3.413800E-01 |
| AfricanAmerican-vs-Asian |
3.314400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.70036999999068E-05 |
| Normal-vs-Female |
5.73999999999852E-05 |
| Male-vs-Female |
4.078000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.241400E-04 |
| Normal-vs-Age(41-60Yrs) |
2.23659999999404E-05 |
| Normal-vs-Age(61-80Yrs) |
2.38750000000065E-05 |
| Normal-vs-Age(81-100Yrs) |
6.945700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.795600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.090000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.962600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.333400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.322000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.993200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.703800E-02 |
| Classical-VS-Follicular |
4.103900E-02 |
| Classical-VS-Other |
8.835800E-02 |
| Classical-VS-Normal |
7.183500E-04 |
| Tall-VS-Follicular |
7.425800E-01 |
| Tall-VS-Other |
3.033200E-01 |
| Tall-VS-Normal |
1.414760E-04 |
| Follicular-VS-Other |
3.095400E-01 |
| Follicular-VS-Normal |
2.17499999999315E-05 |
| Other-VS-Normal |
3.541700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.85989999998715E-06 |
| Normal-vs-N1 |
2.031500E-04 |
| N0-vs-N1 |
7.889000E-01 |
|
|
